10th CML-CAB: virtual meeting, 23 July 2020

The 10th CML Community Advisory Board (CML-CAB) and 20th CML- CAB session to whom we had invited representatives from the companies Incyte and Takeda was held on 23 July 2020.

The main objectives of this first virtual CML-CAB meeting with focus on “global access” were to foster a mutual understanding and to take tangible actions forward for Incyte (who commercializes ponatinib, a third-generation tyrosine kinase inhibitor (TKI) in European Union plus additional countries) and Takeda (who commercializes it in the United States and Australia), the patient community and both in collaboration.

Topics discussed during the meeting included the results of a survey on access to ponatinib conducted by CML Advocates Network in the period March to June 2020, the current patient access status in EU/Europe, Africa, Latin America & Asia, an update on the OPTIC study & the PACE study to address patient community questions about ponatinib safety, dosing, and side effect management, as well as access to mutation testing & BCR-ABL monitoring.

Sessions were followed by discussion rounds, enabling the sharing of different perspectives and offering both sides the chance to ask questions.

Please click below to access the full Executive Summary of this 10th CML-CAB meeting:

CML CAB 2020 Incyte Takeda 23 July 2020 Executive Summary

A big THANK YOU to all participants for making this very first virtual CML-CAB meeting a success!